Coprecipitation on slurry to prepare drug–silica-polymer formulations by compressed antisolvent

https://doi.org/10.1016/j.supflu.2012.01.003Get rights and content

Abstract

This work proposes for the first time a coprecipitation-on-slurry method using CO2 as antisolvent to prepare formulations of a poorly water-soluble drug (tolbutamide) with micrometric silica (60 and 5 μm) and biopolymers. Mixtures were processed from acetone using the batch gas antisolvent method. Polyethylene glycols and Eudragits were selected as polymers capable to modify the drug dissolution behavior. Morphology, size distribution, crystal lattice and dissolution kinetic were characterized. Products were recovered as powders providing a polymer/silica ratio of 50/50, with coarser grains in Eudragits powders compared to PEG's. The size distribution evidenced populations between 10 and 100 μm that were not obtained when TBM was single processed, together with larger agglomerates. In terms of precipitation mechanism, the drug has grown almost unaffected by the presence of silica and polymer in the liquor except for a smaller size, since neither the morphology nor the crystal lattice was significantly changed. The products exhibited substantially different rates of dissolution in accordance with the polymer function: the water-soluble PEGs improved the dissolution rate whereas the water-insoluble Eudragit sustained notably the drug release.

Highlights

► Preparation of drug–silica-biopolymer formulations. ► By CO2 induced coprecipitation on silica slurry in the batch antisolvent version (GAS). ► De-agglomerating effect of silica but no impact on crystallization except on size. ► Polymer coating of drug + silica agglomerates. ► Sustained release or improved dissolution according to polymer type.

Introduction

Preparation of solid formulations is a difficult task in pharmaceutical industry since it has to merge both the therapeutic action and the process requirements. The particles agglomeration can affect the downstream processing operations that transform the active ingredient into a formulation (tabletting, granulation, mixing, blending, coating), and consequently prejudices the formulation homogeneity as well. Agglomeration is very difficult to avoid since it comes from interactions between particles that, being alike, exhibit the same surface characteristics. Size, surface roughness and irregular shape contribute to the cohesion of powders that conversely do not flow well [1]. Addition of glidants to powders, as for instance silica, is a common practice in pharmaceutical industry to aid the powder flowability [1], [2], [3], [4] or to achieve high aerosolization efficiency of inhaled products [5]. For orodispersible tablets, the formulation comprises additional particles to silica such as lubricant or diluent in order to improve the product dispersal efficiency [6], [7].

Employing silica particles as delivery vehicles of therapeutic, biological sensing or imaging agent has gained significant interests lately because of their biocompatibility, versatility and ease of functionalization [8]. Because of their large pore size and their high porous volume, mesoporous silicas (MCM-41, FSM-16, SBA-15) have attracted much attention to formulate hydrophobic drugs of poor solubility in biological fluids, ca class II-drugs of the Biopharmaceutic Classification System. The loading depends on matrix characteristics, on molecular interactions between the drug and the matrix, on the loading method as well [9], [10], [11], [12], [13], [14], [15] and loadings as high as 40–45 wt% were reported for ibuprofen [9], [12]. Regarding the targeted property, the dispersion of the drug in an amorphous state rather than as crystals and the improved wettability of the system are responsible for the enhanced drug dissolution rate [15], [16], [17], [18].

This work examines the feasibility of preparing complex formulations of a hydrophobic drug, tolbutamide, in presence of polymer and silica. The proposed formulation route uses compressed CO2 as an antisolvent to induce both the drug and the polymer coprecipitation on a silica slurry. The starting solution is therefore an organic solvent that contains the drug and polymer as dissolved species and silica as dispersed particles. As outlined before, silica particles can act for the benefit of the preparation route, as passive spacers to deagglomerate API particles, as a wetting agent, or as an active carrier if API molecules are physically sorbed. But presence of particles can also impact the precipitation behavior of the drug and polymer. Indeed, since the proposed route proceeds as a crystallization operation, any substances other than the material to crystallize may act as impurities and therefore are susceptible to affect considerably nucleation and growth behaviors [19]. For polymers, their precipitation by CO2 as antisolvent remains challenging especially for amorphous or semi-crystalline polymers since a CO2-induced plasticization effect [20], [21] often leads to particles agglomeration or to the recovery of a film [22], [23], [24]. The addition of silica to a polymer solution can thus offer an extra surface for the polymer to film upon and consequently to help their recovery as particulate products. To summarize, we can expect that the presence of silica particles in preparations impact in several ways the processing route and the product characteristics as well.

In this work, Tolbutamide (TBM, Fig. 1) was selected as a model hydrophobic drug whose formulation with hydrophilic carriers is one method to improve the dissolution rate. This aryl sulfonylurea compound is an oral hypoglycemic agent used clinically in the treatment of insulin-dependent diabetic patients [25]. Tolbutamide exists as four polymorphs whose crystal pattern, bioavailability and stability are already documented [26]. As for formulations at atmospheric conditions, solid dispersions and inclusion complex of TBM have been obtained with silica [26] and cyclodextrins [27], [28], respectively. Takeuchi's work [26] highlighted the influence of the silica type on the TBM dissolution property, with an increased rate obtained with hydrophilic silica and a sustained release obtained with hydrophobic silica. For TBM – processing by CO2 as antisolvent, the only work reported in literature is author's own investigations [29]: the neat drug was recovered as polyedric particles with a crystal lattice of form III providing that acetone or ethylacetate were used as liquor solvent. The micronization of Tolbutamide was also realized by rapid expansion of supercritical CO2 solutions [30], a method that produced three of the four polymorphs depending on the dissolution conditions (forms I, II and IV). The use of menthol as a co solvent to enhance the TBM solubility was investigated by Lin et al. [31] who evidenced in addition the polymorph conversion of form I to form II after the RESS processing. Regarding the polymeric carriers, polyethylene glycols were selected as water-soluble polymers due to their well-known ability to increase bioavailability of hydrophobic drugs [32], [33], [34], [35], [36]. However, it was complained that drugs prepared with water-soluble polymer carrier tend to be difficult to handle since often sticky or tacky [26]. Furthermore, the target release of a drug is an area that attracts much attention nowadays. Supercritical formulation of tolbutamide with carriers for sustained release was thus attempted as an additional application of the methodology. Eudragit® polymers fulfill requirements of controlled and localized release of the active drug to a very high extend enabling the development of tailor-made solutions [37]. Eudragit® are copolymers of acrylic and methacrylic acid esters branched with various functional groups. The Eudragit RL- and RS-types have a quaternary ammonium as functional group, and contrary to PEGs they are water-insoluble. Nevertheless they are both swellable, so they represent interesting materials for the dispersion of drugs [38], [39], [40], [41], [42].

Preparation of oxide-based formulations of pharmaceutics by supercritical CO2 has been marginally reported in literature, contrary to the coating of oxide particles with polymers [43], [44], [45], [46], [47], [48], [49] or to the co-precipitation of polymer and API [24], [50], [51], [52]. For the preparations of silica–API systems, CO2 can act as a solvent that conveys the drug within a porous material [53], [54] according to the same approach developed for polymer loading [55], [56]. When reported [53], characterizations of formulations revealed that the drug existed mainly in an amorphous state, which contributed to the observed increase of the dissolution rate.

Closer to the procedure hereby proposed is the use of CO2 as antisolvent for the drug [57]. The addition of CO2 to a liquor that contains the dissolved griseofulvin and the silica in suspension provokes the precipitation of the API and leads further to the recovery of an oxide–API solid mixture. The technique was shown to produce a powder of enhanced flowability and of lower size compared to the neat drug, but the presence of silica did not improve the dissolution rate of this poorly water-soluble compound. Finally, a third route uses CO2 as a suspension medium [58]: nanoflakes of itraconazole and nanoparticles of silica were pressurized with supercritical CO2 before being rapidly depressurized through a nozzle. The concept is different from the two previous methods since there are no steps of initial dissolution and recrystallization. Aiming at deagglomerating and mixing the two powders without any solvent, the technique produced a powder of improved flow properties and of better quality upon storage. Dissolution studies evidenced a substantially higher dissolution rate of the preparation compared to the raw API.

The previous cited literature is dealing with binary systems, i.e. API–oxide or polymer–oxide, but to author's best knowledge, the processing of the ternary API–polymer–oxide mixture has not been reported yet. The objective of the work is therefore to propose a coprecipitation-on-slurry method using CO2 as antisolvent to prepare ternary products made of a hydrophobic drug, a silica excipient and a polymer. Polyethylene glycols and Eudragit polymers were selected as polymers capable to modify the dissolution behavior of the drug, whereas two silica of different particle size were selected for processing purpose. The prepared products were characterized for morphology, size distribution and crystalline state and the dissolution kinetic of selected samples was investigated as well.

Section snippets

Materials

Tolbutamide (TBM, chemical structure in Fig. 1) and polyethylene glycols (PEG) of 3400, 4600 and 8000 MW were purchased from Sigma–Aldrich. Acetone (ACE, 99.8% purity) and CO2 (99.5% industrial grade) came from VWR and Air Liquide (France), respectively. Eudragits (RL100, RS 100, L 100) from Evonik Rohm Pharma Polymer (Degussa) were kindly supplied by IMCD (France). In the preparations, Eud RL and RS were used as a mixture, with a RL:RS ratio of 1:2. Silica UP120 (SiO2-UP120, Interchim, France)

Results and discussion

Formulations of TBM/silica/polymer were prepared by GAS, varying the polymer nature, the molecular weight for polyethylene glycols, the oxide characteristics and the ratio between the three components. Conditions of GAS were selected according to our previous investigations on neat TBM that produced the drug as particles of polyedric shape in the range of 250 μm as mean size and in the form III as crystal lattice [29]. The initial liquor was acetone, which was also a suitable solvent for

Conclusion

Powdered formulations of a poorly water soluble drug were successfully prepared by CO2-induced co-precipitation in presence of silica microparticles. In the batch version used in this work, the recovery of a powder was only feasible in presence of silica particles at minimum in equal amount to the polymer, in order to reduce the polymer filming onto the vessel. Formulations were prepared with the 65 μm silica, however, the overlapping between TBM and silica size and shape prejudices the

Acknowledgments

The financial support of the EU (NMP-CT-2005-013524) is acknowledged. Authors also thank Nicolas Fagnon for the PSD measurements.

References (60)

  • S.-C. Shen et al.

    Physical state and dissolution of ibuprofen formulated by co-spray drying with mesoporous silica: effect of pore and particle size

    International Journal of Pharmaceutics

    (2011)
  • V. Ambrogi et al.

    Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate

    European Journal of Pharmaceutical Sciences

    (2007)
  • M.M. Mehanna et al.

    Tadalafil inclusion in microporous silica as effective dissolution enhancer: Optimization of loading procedure and molecular state characterization

    Journal of Pharmaceutical Sciences

    (2011)
  • O.R. Davies et al.

    Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering

    Advanced Drug Delivery Reviews

    (2008)
  • A.R.C. Duarte et al.

    Preparation of acetazolamide composite microparticles by supercritical anti-solvent techniques

    International Journal of Pharmaceutics

    (2007)
  • A.M. Juppo et al.

    Evaluation of solid dispersion particles prepared with SEDS

    International Journal of Pharmaceutics

    (2003)
  • V. Majerik et al.

    Bioavailability enhancement of an active substance by supercritical antisolvent precipitation

    J. Supercritical Fluids

    (2007)
  • H. Takeuchi et al.

    Solid dispersion of tolbutamide prepared with fine silica particles by the spray-drying method

    Powder Technology

    (2004)
  • F. Veiga et al.

    Inclusion complexation of tolbutamide with β-cyclodextrin and hydroxypropyl-β-cyclodextrin

    International Journal of Pharmaceutics

    (1996)
  • E. Suihko et al.

    Complexation with tolbutamide modifies the physicochemical and tableting properties of hydroxypropyl-β-cyclodextrin

    International Journal of Pharmaceutics

    (2001)
  • P. Subra-Paternault et al.

    Solvent effect on tolbutamide crystallization induced by compressed CO2 as antisolvent

    Journal of Crystal Growth

    (2007)
  • C. Leuner et al.

    Improving drug solubility for oral delivery using solid dispersions

    European Journal of Pharmaceutics and Biopharmaceutics

    (2000)
  • E. Badens et al.

    Comparison of solid dispersions produced by supercritical antisolvent and spray-freezing technologies

    International Journal of Pharmaceutics

    (2009)
  • S. Khan et al.

    Physicochemical characterization, drug polymer dissolution and in vitro evaluation of phenacetin and phenylbutazone solid dispersions with polyethylene glycol 8000

    Journal of Pharmaceutical Sciences

    (2011)
  • N. Ubrich et al.

    Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles

    International Journal of Pharmaceutics

    (2005)
  • L. Meka et al.

    Design and evaluation of polymeric coated minitablets as multiple unit gastroretentive floating drug delivery systems for furosemide

    Journal of Pharmaceutical Sciences

    (2009)
  • S-J. Lee et al.

    Nanoparticles of magnetic ferric oxides encapsulated with poly(d,l lactide-co-glycolide) and their application to magnetic resonance imaging contrast agent

    Journal of Magnetism and Magnetic Materials

    (2004)
  • Y. Wang et al.

    Polymer coating/encapsulation of nanoparticles using a supercritical anti-solvent process

    Journal of Supercritical Fluids

    (2004)
  • C. Roy et al.

    Assessment of scCO2 techniques for surface modification of micro- and nano-particles: process design methodology based on solubility

    Journal of Supercritical Fluids

    (2010)
  • C. Garcia-Gonzalez et al.

    Composite fibrous biomaterials for tissue engineering obtained by a supercritical CO2 antisolvent process

    Acta Biomateriala

    (2009)
  • Cited by (13)

    • Application of commercially available mesoporous silica for drug dissolution enhancement in oral drug delivery

      2021, European Journal of Pharmaceutical Sciences
      Citation Excerpt :

      This process has also been performed without silica, using only a drug and a specific polymer as the carrier, but this set-up is known to be problematic due to a CO2-induced plasticisation effect, and the consequent particle agglomeration. The addition of silica particles has been shown to help prevent this (Murillo-Cremaes et al., 2014; Subra-Paternault et al., 2012). Miura et al. (2010) investigated the enhancement of the dissolution rate of a poorly water-soluble drug K-832 by adsorption into Sylysia® 350 using the scCO2 method and the solvent immersion method, with dichloromethane as solvent.

    • Preparation of naproxen-excipient formulations by CO<inf>2</inf> precipitation on a slurry

      2014, Powder Technology
      Citation Excerpt :

      Conditions and product characteristics are given in Table 2. Conditions and API:excipient ratio were selected on the basis of preceding results with silica [21] or of particle generation upon operating conditions [17]. The work focused on screening the impact of various excipients and/or procedure on the physical and dissolution characteristics of powders prepared by this new method for which literature background is rare.

    • Particle Formation Using Sub- and Supercritical Fluids

      2014, Supercritical Fluid Technology for Energy and Environmental Applications
    • Prediction of solubilities of solid solutes in carbon dioxide-expanded organic solvents using the predictive Soave-Redlich-Kwong (PSRK) equation of state

      2013, Chemical Engineering Research and Design
      Citation Excerpt :

      In addition, Kerler et al. (2004), Wei et al. (2002) and Caravati et al. (2006) applied the CO2-expanded solvents as unique and versatile media for performing homogeneous and heterogeneous reactions. Furthermore, micronization of pharmaceutical compounds and production of pharmaceutical composite particles using CO2-expanded organic solvents was also investigated as the batch supercritical antisolvent process (Thakur et al., 2009; Uzun et al., 2011; Subra-Paternault et al., 2012). In the batch supercritical antisolvent process, CO2 is used as an antisolvent and dissolved in an organic solution.

    View all citing articles on Scopus
    View full text